Patients with oesophageal and gastric cancers often present with weight loss and poor nutrition(Reference Gencer, Kästle-Larralde and Pilz1). Nutritional status is a predictive factor in post-operative outcomes(Reference Han-Geurts, Hop and Tran2). Neo-adjuvant chemotherapy followed by surgery is the treatment of choice for the majority of these patients(Reference Mezhir, Tang and Coit3). The effects of chemotherapy on weight loss and nutrition is of clinical importance(Reference Bower and Martin4).
A prospective cohort of patients undergoing neo-adjuvant chemotherapy prior to surgical resection for oesophageal and gastric cancers within a major teaching hospital were assessed. Primary end points included weight change during neo-adjuvant chemotherapy and extent of dietetic intervention.
Fifty-two patients were assessed. Sixty-seven percent (n 34) of patients were noted to have weight loss between the time of diagnosis and completion of pre-operative chemotherapy. 21% (n 11) of patients gained weight, the average percentage weight gain being 5%. The average percentage weight loss was 6% (+13% to −22%). Thirteen percent (n 7) of patients suffered severe weight loss (>10% total body weight). Eighteen percent (n 10) of patients received dietetic intervention which included oral nutritional supplements (n 4), nasogastric supplements (n 2) and nasojejunal supplements (n 4). Of the patients that gained weight, only 18% (n 2) received dietetic intervention.
The majority of patients undergoing neo-adjuvant chemotherapy prior to surgery for oesophageal and gastric cancers experienced weight loss during the period of treatment. Early and aggressive nutritional assessment and support may help prevent or reduce pre-operative weight loss and improve patient outcomes.
